October 21, 2022 05:59 AM EDTUpdated 07:27 AM

Former Allergan exec heads to Revance as it challenges Botox; Mark Pruzanski surrounds himself with more teammates

Alex Hoffman

Senior Editor

Kathy Wong

Editor

→ Revance feels like it has a competitive advantage over AbbVie’s blockbuster Botox with only biannual injections of its freshly approved Daxxify, as opposed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Former Allergan exec heads to Revance as it challenges Botox; Mark Pruzanski surrounds himself with more teammates

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

For­mer Al­ler­gan ex­ec heads to Re­vance as it chal­lenges Botox; Mark Pruzan­s­ki sur­rounds him­self with more team­mates

Senior Editor

Editor

Sign up to read this article for free.

Former Allergan exec heads to Revance as it challenges Botox; Mark Pruzanski surrounds himself with more teammates